Now showing items 1-6 of 6
Pharmacovigilance in hospice/palliative care: rapid report of net clinical effect of metoclopramide
((C) Mary Ann Liebert, Inc., 2012-07-20)
Background: Understanding the performance of prescribed medications in day-to-day practice is important to minimize harm, maximize clinical benefits, and, eventually, better target the people who are most likely to benefit, ...
End-of-life research: do we need to build proxy consent into all clinical trial protocols studying the terminal phase?
(Mary Ann Liebert, Inc., 2012-09-04)
Research into symptoms that occur at the end of life is paramount for ensuring we provide the best possible care for patients in the terminal phase, yet obtaining informed consent from the study participant is not possible ...
The longitudinal pattern of response when morphine is used to treat chronic refractory dyspnea
(Mary Ann Liebert, Inc., 2013-07-22)
Background: While evidence supports using sustained release morphine for chronic refractory breathlessness, little is known about the longitudinal pattern of breathlessness intensity as people achieve symptomatic benefit. The ...
A collateral benefit of research in palliative care
(Mary Ann Liebert, Inc., 2011-09-12)
A collateral benefit of being in a research-active clinical unit is that there is evidence that better care is delivered. The most dramatic data to date demonstrate that in cardiology, research- active cardiology departments ...
Core medicines for quality care of the dying
(Mary Ann Liebert, Inc., 2013-05-16)
The proposal by Lindqvist and colleagues of four essential medicines for the control of terminal symptoms is commendable. Having a finite essential medication list facilitates prescribers to prescribe and pharmacies to ...
An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice
(Mary Ann Liebert, Inc., 2012-02-21)
Background: Medication registration currently requires evidence of safety and efficacy from adequately powered phase 3 studies. Pharmacovigilance (phase 4 studies, postmarketing data, adverse drug reaction reporting) provide ...